NI201100092A - Pirrolidinas - Google Patents

Pirrolidinas

Info

Publication number
NI201100092A
NI201100092A NI201100092A NI201100092A NI201100092A NI 201100092 A NI201100092 A NI 201100092A NI 201100092 A NI201100092 A NI 201100092A NI 201100092 A NI201100092 A NI 201100092A NI 201100092 A NI201100092 A NI 201100092A
Authority
NI
Nicaragua
Prior art keywords
compounds
formula
preparation
pelvic pain
chronic pelvic
Prior art date
Application number
NI201100092A
Other languages
English (en)
Spanish (es)
Inventor
Neil Dack Kevin
Elizabeth Skerratt Sarah
Edward John Mills James
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NI201100092A publication Critical patent/NI201100092A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NI201100092A 2008-11-10 2011-05-09 Pirrolidinas NI201100092A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11286908P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
NI201100092A true NI201100092A (es) 2011-10-31

Family

ID=41503565

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100092A NI201100092A (es) 2008-11-10 2011-05-09 Pirrolidinas

Country Status (31)

Country Link
US (1) US8278343B2 (enExample)
EP (1) EP2364296A1 (enExample)
JP (1) JP2012508225A (enExample)
KR (1) KR20110083733A (enExample)
CN (1) CN102209710A (enExample)
AP (1) AP2011005728A0 (enExample)
AR (1) AR074314A1 (enExample)
AU (1) AU2009312427B2 (enExample)
BR (1) BRPI0920924A2 (enExample)
CA (1) CA2741589A1 (enExample)
CL (1) CL2011001034A1 (enExample)
CO (1) CO6382112A2 (enExample)
CR (1) CR20110217A (enExample)
CU (1) CU20110093A7 (enExample)
DO (1) DOP2011000127A (enExample)
EA (1) EA201100549A1 (enExample)
EC (1) ECSP11011032A (enExample)
GE (1) GEP20125607B (enExample)
IL (1) IL212490A0 (enExample)
MA (1) MA32782B1 (enExample)
MX (1) MX2011004903A (enExample)
NI (1) NI201100092A (enExample)
NZ (1) NZ592311A (enExample)
PA (1) PA8848001A1 (enExample)
PE (1) PE20110663A1 (enExample)
SV (1) SV2011003896A (enExample)
TN (1) TN2011000211A1 (enExample)
TW (1) TW201022234A (enExample)
UY (1) UY32228A (enExample)
WO (1) WO2010052625A1 (enExample)
ZA (1) ZA201104310B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
JPWO2013176220A1 (ja) * 2012-05-25 2016-01-14 国立大学法人京都大学 概日リズム調整
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
WO2022272060A1 (en) 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds
JP2024524981A (ja) * 2021-06-24 2024-07-09 レザボア ニューロサイエンス,インコーポレイテッド Ep2アンタゴニスト化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5319099A (en) * 1991-01-21 1994-06-07 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents
ES2337887T3 (es) * 2001-12-20 2010-04-30 Merck Serono Sa Derivados de pirrolidina en calidad de moduladores de prostaglandina.
WO2007005176A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
DE102006039912A1 (de) * 2006-08-25 2008-03-20 Bayer Healthcare Ag Substituierte Spirotetronsäuren und ihre Verwendung
MX2009011998A (es) * 2007-05-10 2009-11-19 Pfizer Ltd Derivados de azetidina y su uso como antagonistas de prostaglandina e2.

Also Published As

Publication number Publication date
CN102209710A (zh) 2011-10-05
SV2011003896A (es) 2011-07-05
BRPI0920924A2 (pt) 2016-10-04
ECSP11011032A (es) 2011-06-30
CO6382112A2 (es) 2012-02-15
EP2364296A1 (en) 2011-09-14
ZA201104310B (en) 2012-02-29
EA201100549A1 (ru) 2011-12-30
CA2741589A1 (en) 2010-05-14
CU20110093A7 (es) 2012-01-31
IL212490A0 (en) 2011-06-30
PE20110663A1 (es) 2011-09-23
AU2009312427A1 (en) 2010-05-14
AU2009312427B2 (en) 2011-10-20
WO2010052625A1 (en) 2010-05-14
MX2011004903A (es) 2011-05-30
UY32228A (es) 2010-06-30
US8278343B2 (en) 2012-10-02
AR074314A1 (es) 2011-01-05
TN2011000211A1 (fr) 2012-12-17
US20100120793A1 (en) 2010-05-13
CL2011001034A1 (es) 2011-11-11
JP2012508225A (ja) 2012-04-05
DOP2011000127A (es) 2011-07-15
GEP20125607B (en) 2012-08-10
TW201022234A (en) 2010-06-16
AP2011005728A0 (en) 2011-06-30
KR20110083733A (ko) 2011-07-20
MA32782B1 (fr) 2011-11-01
CR20110217A (es) 2011-05-12
PA8848001A1 (es) 2010-06-28
NZ592311A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
ECSP11011032A (es) Pirrolidinas
PA8827901A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
SV2011003970A (es) Derivados de sulfonamida
PA8779201A1 (es) Derivados de piridina
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
CU24091B1 (es) Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden
CR11101A (es) Azetidinas
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
CL2009000368A1 (es) 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
SI3044206T1 (en) (3z,5s)-5-(hydroxymethyl)-1-((2 -methyl-1,1 -biphenyl-4-yl)carbonyl)pyrrolidin-3-one o-methyloxime as oxytocin / vasopressin v1a receptors antagonists for the treatment of preterm labor
UA90763C2 (ru) Производные пиразола, способ их получения, фармацевтический состав на их основе и их применение
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
CY1119710T1 (el) Συντηγμενες θειαζολο- και οξαζολο-πυριμιδινονες
AR062114A1 (es) Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos.
SV2010003725A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX2019000498A (es) Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos.
CO6690116A1 (es) Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen
CU20110133A7 (es) Derivados de (4-terc-butilpiperazin-2-il)(piperazin-1-il)metanona-n-carboxamida
ATE525360T1 (de) Neuartige imidazolinylmethyl-aryl-sulfonamide
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
BR112023021918A2 (pt) Composto como antagonista do receptor de adenosina a2a e composição farmacêutica compreendendo o mesmo
CO6331339A2 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3
CR20170536A (es) Derivados de etinilo
CR11790A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
UA111595C2 (uk) ПІРАЗИНОВІ ПОХІДНІ ЯК ENaC БЛОКАТОРИ